Aneta Konwerska, Beata Janik, Agnieszka Malinska, Wojciech Witkiewicz and Maciej Zabel
Recently, the most significant studies in the field of angiogenesis are related to trials concerning the evaluation of the prognostic significance of endothelial markers. By using an estimation of the expression of endothelial cell markers, immunohistochemical studies can assess for the continuity of the vascular intima, as well as allow for the distinction of early, late and mature forms of endothelial cells. The determination of the endothelial cell phenotype using markers such as CD34, CD31, CD133, e-NOS and von Willebrand factor may provide a valuable tool for the monitoring of both normal physiology as well as neoplastic diseases.
Karolina Sterzynska, Patrycja Sujka-Kordowska and Wojciech Witkiewicz
Currently available approaches for treating patients with ischemic heart disease include medical therapy or coronary revascularization by surgical procedures, like coronary artery bypass grafting (CABG). Bypass grafting often provides dramatic relief from the symptoms of myocardial ischemia. However, a significant number of patients are not candidates for these kind of treatment or achieve incomplete revascularization. Hence, an alternative treatment strategy such as therapeutic angiogenesis has emerged as a new method for patients with inoperable coronary artery disease. Recently it has been demonstrated that angiogenic growth factors, like vascular endothelial growth factor or fibroblast growth factor, can improve myocardial perfusion and function.